Next Article in Journal
The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study
Next Article in Special Issue
hiPSCs Derived Cardiac Cells for Drug and Toxicity Screening and Disease Modeling: What Micro- Electrode-Array Analyses Can Tell Us
Previous Article in Journal
Postnatal Development of the Subcellular Structures and Purinergic Signaling of Deiters’ Cells along the Tonotopic Axis of the Cochlea
Previous Article in Special Issue
Molecular Mechanisms of Cardiac Remodeling and Regeneration in Physical Exercise
Open AccessCommunication

Blocking LFA-1 Aggravates Cardiac Inflammation in Experimental Autoimmune Myocarditis

1
Medizinische Klinik und Poliklinik I, Klinikum der Universität, LMU Munich, 81377 Munich, Germany
2
Walter Brendel Centre of Experimental Medicine, University Hospital, LMU Munich, 82152 Planegg-Martinsried, Germany
3
Institute of Cardiovascular Physiology and Pathophysiology, Biomedical Center, LMU Munich, 82152 Planegg-Martinsried, Germany
4
German Center for Cardiovascular Research, Partner Site Munich Heart Alliance, 80802 Munich, Germany
5
Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, 8952 Schlieren, Switzerland
*
Author to whom correspondence should be addressed.
Contributed equally.
Cells 2019, 8(10), 1267; https://doi.org/10.3390/cells8101267
Received: 17 September 2019 / Revised: 9 October 2019 / Accepted: 9 October 2019 / Published: 17 October 2019
(This article belongs to the Special Issue Stem Cell Research on Cardiology)
The lymphocyte function-associated antigen 1 (LFA-1) is a member of the beta2-integrin family and plays a pivotal role for T cell activation and leukocyte trafficking under inflammatory conditions. Blocking LFA-1 has reduced or aggravated inflammation depending on the inflammation model. To investigate the effect of LFA-1 in myocarditis, mice with experimental autoimmune myocarditis (EAM) were treated with a function blocking anti-LFA-1 antibody from day 1 of disease until day 21, the peak of inflammation. Cardiac inflammation was evaluated by measuring infiltration of leukocytes into the inflamed cardiac tissue using histology and flow cytometry and was assessed by analysis of the heart weight/body weight ratio. LFA-1 antibody treatment severely enhanced leukocyte infiltration, in particular infiltration of CD11b+ monocytes, F4/80+ macrophages, CD4+ T cells, Ly6G+ neutrophils, and CD133+ progenitor cells at peak of inflammation which was accompanied by an increased heart weight/body weight ratio. Thus, blocking LFA-1 starting at the time of immunization severely aggravated acute cardiac inflammation in the EAM model. View Full-Text
Keywords: myocarditis; inflammation; leukocytes myocarditis; inflammation; leukocytes
Show Figures

Figure 1

MDPI and ACS Style

Weckbach, L.T.; Uhl, A.; Boehm, F.; Seitelberger, V.; Huber, B.C.; Kania, G.; Brunner, S.; Grabmaier, U. Blocking LFA-1 Aggravates Cardiac Inflammation in Experimental Autoimmune Myocarditis. Cells 2019, 8, 1267. https://doi.org/10.3390/cells8101267

AMA Style

Weckbach LT, Uhl A, Boehm F, Seitelberger V, Huber BC, Kania G, Brunner S, Grabmaier U. Blocking LFA-1 Aggravates Cardiac Inflammation in Experimental Autoimmune Myocarditis. Cells. 2019; 8(10):1267. https://doi.org/10.3390/cells8101267

Chicago/Turabian Style

Weckbach, Ludwig T.; Uhl, Andreas; Boehm, Felicitas; Seitelberger, Valentina; Huber, Bruno C.; Kania, Gabriela; Brunner, Stefan; Grabmaier, Ulrich. 2019. "Blocking LFA-1 Aggravates Cardiac Inflammation in Experimental Autoimmune Myocarditis" Cells 8, no. 10: 1267. https://doi.org/10.3390/cells8101267

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop